Aortic stenosis at young adult age

Expert Review of Cardiovascular Therapy

Volumn 3, Issue 6, 2005, Pages 1087-1098

  Yap, Sing Chien ^a   Takkenberg, Johanna J M ^a   Witsenburg, Maarten ^a   Meijboom, Folkert J ^a   Roos Hesselink, Jolien W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adrenergic antagonists; Angiotensin converting enzyme inhibitor; Aortic disease; Aortic valve stenosis; Congenital heart defects; Exercise; HMG CoA reductase inhibitors; Pregnancy

Indexed keywords

ANGIOTENSIN; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO;

ADULT; AGE DISTRIBUTION; ALOPECIA; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; AORTA DISSECTION; AORTA STENOSIS; AORTA VALVE REGURGITATION; AORTA VALVE REPLACEMENT; ARTERY DILATATION; ASCENDING AORTA; BACTERIAL ENDOCARDITIS; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONGENITAL MALFORMATION; DIABETES MELLITUS; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EXERCISE; EXERCISE TEST; FETUS RISK; FETUS WASTAGE; GENETIC COUNSELING; GENETIC RISK; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE ARRHYTHMIA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; HYPOTENSION; IMMUNOHISTOCHEMISTRY; INOTROPISM; INTRAUTERINE GROWTH RETARDATION; MORBIDITY; MORTALITY; NONHUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE THROMBOSIS; PRACTICE GUIDELINE; PREGNANCY; PREMATURE LABOR; PRIMARY PREVENTION; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; SAFETY; SECONDARY PREVENTION; SEX DIFFERENCE; SMOKING; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TRANSLUMINAL VALVULOPLASTY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AORTIC VALVE STENOSIS; FEMALE; HUMANS; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

EID: 28644440331     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.3.6.1087     Document Type: Review

References (84)

1. Roberts WC. The congenitally bicuspid aortic valve. A study of 85 autopsy cases. Am. J. Cardiol. 26(1), 72-83 (1970).
2. Larson EW, Edwards WD. Risk factors for aortic dissection: a necropsy study of 161 cases. Am. J. Cardiol. 53(6), 849-855 (1984).
3. Fenoglio JJ Jr, McAllister HA Jr, DeCastro CM, Davia JE, Cheitlin MD. Congenital bicuspid aortic valve after age 20. Am. J. Cardiol. 39(2), 164-169 (1977).
4. Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation 111(7), 920-925 (2005).
5. Beppu S, Suzuki S, Matsuda H et al. Rapidity of progression of aortic stenosis in patients with congenital bicuspid aortic valves. Am. J. Cardiol. 71(4), 322-327 (1993).
6. Chan KL, Ghani M, Woodend K, Burwash IG. Case-controlled study to assess risk factors for aortic stenosis in congenitally bicuspid aortic valve. Am. J. Cardiol. 88(6), 690-693 (2001).
7. Horstkotte D, Loogen F. The natural history of aortic valve stenosis. Eur. Heart J. 9(Suppl. E), 57-64 (1988).
8. Ross J Jr, Braunwald E. Aortic stenosis. Circulation 38(Suppl. 1), 61-67 (1968).
9. Pellikka PA, Nishimura RA, Bailey KR, Tajik AJ. The natural history of adults with asymptomatic, hemodynamically significant aortic stenosis. J. Am. Coll. Cardiol. 15(5), 1012-1017 (1990).
10. Rosenhek R, Binder T, Porenta G et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N. Engl. J. Med. 343(9), 611-617 (2000).
11. Takkenberg JJ, Puvimanasinghe JP, Grunkemeier GL. Simulation models to predict outcome after aortic valve replacement. Ann. Thorac. Surg. 75(5), 1372-1376 (2003).
12. Lindblom D, Lindblom U, Qvist J, Lundstrom H. Long-term relative survival rates after heart valve replacement. J. Am. Coll. Cardiol. 15(3), 566-573 (1990).
13. Bonow RO, Carabello B, de Leon AC Jr et al. ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association. Task force on practice guidelines (Committee on management of patients with valvular heart disease). J. Am. Coll. Cardiol. 32(5), 1486-1588 (1998).
14. Otto CM, Burwash IG, Legget ME et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 95(9), 2262-2270 (1997).
15. Rosenhek R, Klaar U, Schemper M et al. Mild and moderate aortic stenosis. Natural history and risk stratification by echocardiography. Eur. Heart J. 25(3), 199-205 (2004).
16. Weber M, Arnold R, Rau M et al. Relation of N-terminal pro-B-type natriuretic peptide to severity of valvular aortic stenosis. Am. J. Cardiol. 94(6), 740-745 (2004).
17. Gerber IL, Stewart RA, Legget ME et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 107(14), 1884-1890 (2003).
18. Bergler-Klein J, Klaar U, Heger M et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 109(19), 2302-2308 (2004).
19. Reich O, Tax P, Marek J et al. Long term results of percutaneous balloon valvoplasty of congenital aortic stenosis: independent predictors of outcome. Heart 90(1), 70-76 (2004).
20. Rosenfeld HM, Landzberg MJ, Perry SB et al. Balloon aortic valvuloplasty in the young adult with congenital aortic stenosis. Am. J. Cardiol. 73(15), 1112-1117 (1994).
21. Rahimtoola SH. Choice of prosthetic heart valve for adult patients. J. Am. Coll. Cardiol. 41(6), 893-904 (2003).
22. Elkayam U, Bitar F. Valvular heart disease and pregnancy: part II: prosthetic valves. J. Am. Coll. Cardiol. 46(3), 403-410 (2005).
23. De Sa M, Moshkovitz Y, Butany J, David TE. Histologic abnormalities of the ascending aorta and pulmonary trunk in patients with bicuspid aortic valve disease: clinical relevance to the ross procedure. J. Thorac. Cardiovasc. Surg. 118(4), 588-594 (1999).
24. Schmidtke C, Bechtel M, Hueppe M, Sievers HH. Time course of aortic valve function and root dimensions after subcoronary ross procedure for bicuspid versus tricuspid aortic valve disease. Circulation 104(12 Suppl. 1), I21-I24 (2001).
25. Lamas CC, Eykyn SJ. Bicuspid aortic valve-a silent danger: analysis of 50 cases of infective endocarditis. Clin. Infect. Dis. 30(2), 336-341 (2000).
26. Fedak PW, David TE, Borger M et al. Bicuspid aortic valve disease: recent insights in pathophysiology and treatment. Expert Rev. Cardiovasc. Ther. 3(2), 295-308 (2005).
27. Niwa K, Perloff JK, Bhuta SM et al. Structural abnormalities of great arterial walls in congenital heart disease: light and electron microscopic analyses. Circulation 103(3), 393-400 (2001).
28. Bonderman D, Gharehbaghi-Schnell E, Wollenek G et al. Mechanisms underlying aortic dilatation in congenital aortic valve malformation. Circulation 99(16), 2138-2143 (1999).
29. Katz NM, Buckley MJ, Liberthson RR. Discrete membranous subaortic stenosis. Report of 31 patients, review of the literature, and delineation of management. Circulation 56(6), 1034-1038 (1977).
30. Nistri S, Sorbo MD, Marin M et al. Aortic root dilatation in young men with normally functioning bicuspid aortic valves. Heart 82(1), 19-22 (1999).
31. Pachulski RT, Weinberg AL, Chan KL. Aortic aneurysm in patients with functionally normal or minimally stenotic bicuspid aortic valve. Am. J. Cardiol. 67(8), 781-782 (1991).
32. Hahn RT, Roman MJ, Mogtader AH, Devereux RB. Association of aortic dilation with regurgitant, stenotic and functionally normal bicuspid aortic valves. J. Am. Coll. Cardiol. 19(2), 283-288 (1992).
33. Yasuda H, Nakatani S, Stugaard M et al. Failure to prevent progressive dilation of ascending aorta by aortic valve replacement in patients with bicuspid aortic valve: comparison with tricuspid aortic valve. Circulation 108(Suppl. 1), II291-II294 (2003).
34. Nataatmadja M, West M, West J et al. Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm. Circulation 108(Suppl. 1), II329-II334 (2003).
35. Ferencik M, Pape LA. Changes in size of ascending aorta and aortic valve function with time in patients with congenitally bicuspid aortic valves. Am. J. Cardiol. 92(1), 43-46 (2003).
36. Roberts CS, Roberts WC. Dissection of the aorta associated with congenital malformation of the aortic valve. J. Am. Coll. Cardiol. 17(3), 712-716 (1991).
37. Borger MA, Preston M, Ivanov J et al. Should the ascending aorta be replaced more frequently in patients with bicuspid aortic valve disease? J. Thorac. Cardiovasc. Surg. 128(5), 677-683 (2004).
38. Maron BJ. Sudden death in young athletes. N. Engl. J. Med. 349(11), 1064-1075 (2003).
39. Driscoll DJ, Edwards WD. Sudden unexpected death in children and adolescents. J. Am. Call. Cardiol. 5(Suppl. 6), 118B-121B (1985).
40. Bonow RO, Cheitlin MD, Crawford MH, Douglas PS. Task Force 3: valvular heart disease. J. Am. Coll. Cardiol. 45(8), 1334-1340 (2005).
41. Mitchell JH, Haskell W, Snell P, Van Camp SP. Task Force 8: classification of sports. J. Am. Coll. Cardiol. 45(8), 1364-1367 (2005).
42. Gibbons RJ, Balady GJ, Bricker JT et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to update the 1997 exercise testing guidelines). J. Am. Coll. Cardiol. 40(8), 1531-1540 (2002).
43. Amato MC, Moffa PJ, Werner KE, Ramires JA. Treatment decision in asymptomatic aortic valve stenosis: role of exercise testing. Heart 86(4), 381-386 (2001).
44. Das P, Rimington H, Chambers J. Exercise testing to stratify risk in aortic stenosis. Eur. Heart J. 26, 1309-1313 (2005).
45. Arias F, Pineda J. Aortic stenosis and pregnancy. J. Reprod. Med. 20(4), 229-232 (1978).
46. Hameed A, Karaalp IS, Tummala PP et al. The effect of valvular heart disease on maternal and fetal outcome of pregnancy. J. Am. Coll. Cardiol. 37(3), 893-899 (2001).
47. Lao TT, Sermer M, MaGee L, Farine D, Colman JM. Congenital aortic stenosis and pregnancy - a reappraisal. Am. J. Obstet. Gynecol. 169(3), 540-545 (1993).
48. Silversides CK, Colman JM, Sermer M, Farine D, Siu SC. Early and intermediate-term outcomes of pregnancy with congenital aortic stenosis. Am. J. Cardiol. 91(11), 1386-1389 (2003).
49. Lao TT, Adelman AG, Sermer M, Colman JM. Balloon valvuloplasty for congenital aortic stenosis in pregnancy. Br. J. Obstet. Grynaecol. 100(12), 1141-1142 (1993).
50. Banning AP, Pearson JF, Hall RJ. Role of balloon dilatation of the aortic valve in pregnant patients with severe aortic stenosis. Br. Heart J. 70(6), 544-545 (1993).
51. Bernal JM, Miralles PJ. Cardiac surgery with cardiopulmonary bypass during pregnancy. Obstet. Gynecol. Surv. 41(1), 1-6 (1986).
52. Reimold SC, Rutherford JD. Clinical practice. Valvular heart disease in pregnancy. N. Engl. J. Med. 349(1), 52-59 (2003).
53. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch. Intern. Med. 160(2), 191-196 (2000).
54. Obergfell A, Langenfeld H, Hopp H, Steigerwald U, Grossmann R. Thrombosis of a prosthetic aortic valve during pregnancy despite therapeutic dosage of Nadroparin. Thromb. Haemost. 91(4), 839-840 (2004).
55. Huntington K, Hunter AG, Chan KL. A prospective study to assess the frequency of familial clustering of congenital bicuspid aortic valve. J. Am. Coll. Cardiol. 30(7), 1809-1812 (1997).
56. Driscoll DJ, Michels VV, Gersony WM et al. Occurrence risk for congenital heart defects in relatives of patients with aortic stenosis, pulmonary stenosis, or ventricular septal defect. Circulation 87(Suppl. 2), I114-I120 (1993).
57. Whittemore R, Hobbins JC, Engle MA. Pregnancy and its outcome in women with and without surgical treatment of congenital heart disease. Am. J. Cardiol. 50(3), 641-651 (1982).
58. Nora JJ, Nora AH. Maternal transmission of congenital heart diseases: new recurrence risk figures and the questions of cytoplasmic inheritance and vulnerability to teratogens. Am. J. Cardiol. 59(5), 459-463 (1987).
59. Cripe L, Andelfinger G, Martin LJ, Shooner K, Benson DW. Bicuspid aortic valve is heritable. J. Am. Coll. Cardiol. 44(1), 138-143 (2004).
60. Lewin MB, McBride KL, Pignatelli R et al. Echocardiographic evaluation of asymptomatic parental and sibling cardiovascular anomalies associated with congenital left ventricular outflow tract lesions. Pediatrics 114(3), 691-696 (2004).
61. Roos-Hesselink JW, Scholzel BE, Heijdra RJ et al. Aortic valve and aortic arch pathology after coarctation repair. Heart 89(9), 1074-1077 (2003).
62. Fernandes SM, Sanders SP, Khairy P et al. Morphology of bicuspid aortic valve in children and adolescents. J. Am. Coll. Cardiol. 44(8), 1648-1651 (2004).
63. O'Brien KD, Reichenbach DD, Marcovina SM et al. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler. Thromb. Vasc. Biol. 16(4), 523-532 (1996).
64. O'Brien KD, Kuusisto J, Reichenbach DD et al. Osteopontin is expressed in human aortic valvular lesions. Circulation 92(8), 2163-2168 (1995).
65. Mohler ER III, Gannon F, Reynolds C et al. Bone formation and inflammation in cardiac valves. Circulation 103(11), 1522-1528 (2001).
66. Wallby L, Janerot-Sjoberg B, Steffensen T, Broqvist M. T lymphocyte infiltration in nonrheumatic aortic stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves. Heart 88(4), 348-351 (2002).
67. Stewart BF, Siscovick D, Lind BK et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular health study. J. Am. Coll. Cardiol. 29(3), 630-634 (1997).
68. Wu B, Elmariah S, Kaplan FS, Cheng G, Mohler ER III. Paradoxical effects of statins on aortic valve myofibroblasts and osteoblasts: implications for end-stage valvular heart disease. Arterioscler. Thromb. Vasc. Biol. 25(3), 592-597 (2005).
69. Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am. J. Cardiol. 88(6), 693-695 (2001).
70. Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J. Am. Coll. Cardiol. 40(10), 1723-1730 (2002).
71. Novaro GM, Tiong IY, Pearce GL et al. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 104(18), 2205-2209 (2001).
72. Rosenhek R, Rader F, Loho N et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 110(10), 1291-1295 (2004).
73. Pohle K, Maffert R, Ropers D et al. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 104(16), 1927-1932 (2001).
74. Shavelle DM, Takasu J, Budoff MJ et al. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 359(9312), 1125-1126 (2002).
75. Antonini-Canterin F, Zuppiroli A, Popescu BA et al. Effect of statins on the progression of bioprosthetic aortic valve degeneration. Am. J. Cardiol. 92(12), 1479-1482 (2003).
76. Cowell SJ, Newby DE, Prescott RJ et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N. Engl. J. Med. 352(23), 2389-2397 (2005).
77. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342(3), 145-153 (2000).
78. Lonn E. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis. Curr. Atheroscler. Rep. 4(5), 363-372 (2002).
79. O'Brien KD, Shavelle DM, Caulfield MT et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 106(17), 2224-2230 (2002).
80. O'Brien KD, Probstfield JL, Caulfield MT et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch. Intern. Med. 165(8), 858-862 (2005).
81. O'Brien KD, Zhao XQ, Shavelle DM et al. Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. J. Investig. Med. 52(3), 185-191 (2004).
82. Chockalingam A, Venkatesan S, Subramaniam T et al. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). Am. Heart J. 147(4), E19 (2004).
83. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term β-adrenergic blockade in Marfan's syndrome. N. Engl. J. Med. 330(19), 1335-1341 (1994).
84. Milewicz DM, Dietz HC, Miller DC. Treatment of aortic disease in patients with Marfan syndrome. Circulation 111(11), E150-E157 (2005).